Physician profile
Drake Everson
NPI 1255824512
$921.36
in general payments reported to CMS, 2019-2025
16 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.13 · 2021: $85.56 · 2022: $122 · 2023: $158 · 2024: $194 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.68 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $147.40 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $101.05 | 2024-2025 | |
| Esperion Therapeutics, INC. | $85.56 | 2021 | |
| Abbvie INC. | $82.83 | 2023-2025 | |
| Glaxosmithkline, LLC. | $65.26 | 2023-2025 | Trelegy Ellipta, Bexsero, Pediarix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.72 | 2025 | Caplyta |
| Amgen INC. | $30.69 | 2023-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $18.66 | 2024 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.07 | 2025 | Gemtesa |
| Exact Sciences Corporation | $16.14 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $15.13 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2024 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $13.92 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2025 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $12.93 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drake Everson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.